Related Experiment Video

Updated: Jun 26, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Role of increased ROS dissipation in prevention of T1D

Jing Chen1, Aaron M Gusdon, Terri C Thayer

  • 1Department of Pathology, University of Florida College of Medicine, Gainesville, Florida 32610-0275, USA.

Annals of the New York Academy of Sciences
|January 6, 2009
PubMed

Insights

Protecting pancreatic beta cells from reactive oxygen species (ROS) can prevent type 1 diabetes (T1D). ALR mice with enhanced ROS dissipation resist T1D, demonstrating this protective mechanism against autoimmune destruction.

Area of Science:

  • Immunology
  • Endocrinology
  • Genetics

Background:

  • Autoimmune type 1 diabetes (T1D) involves pancreatic beta cell destruction.
  • Reactive oxygen species (ROS) are key mediators in beta cell death during T1D development.
  • Protecting beta cells is a therapeutic strategy for T1D and islet transplantation.

Purpose of the Study:

  • To investigate the role of enhanced ROS dissipation in preventing autoimmune T1D.
  • To evaluate the protective effects of elevated ROS dissipation on beta cells.

Main Methods:

  • Utilized the ALR mouse strain, selected for resistance to alloxan-induced diabetes.
  • Employed genetic mapping, conplastic and congenic mouse studies, and cell line investigations.
  • Assessed systemic and pancreatic ROS dissipation levels in ALR mice.

Main Results:

  • ALR mice exhibit elevated systemic and pancreatic ROS dissipation.
  • Genetic mapping identified diabetes-protective loci derived from the ALR strain.
  • Elevated ROS dissipation was confirmed to protect ALR beta cells from autoimmune destruction.

Conclusions:

  • Enhanced ROS dissipation is a significant factor in preventing T1D development.
  • Elevated ROS dissipation protects pancreatic beta cells from autoimmune-mediated destruction.
  • This mechanism offers a potential strategy for T1D prevention and islet graft protection.

More Related Videos

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...